Bristol Myers Squibb stock: BMS joins Erasca cancer trial
Published on 11/18/2026 at 15:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew pancreatic cancer collaboration
- Bristol Myers Squibb will sponsor a Phase 1/2 study combining navlimetostat with Erasca's ERAS-0015.
- The trial will target MTAP-deleted pancreatic ductal adenocarcinoma.
- Both companies will retain development and commercial rights to their respective compounds.
Bristol Myers Squibb has entered a clinical trial collaboration and supply agreement with Erasca to study Erasca's ERAS-0015 together with BMS's investigational drug navlimetostat. Erasca announced the agreement on November 17, 2026, according to BioSpace, which reproduced the Globe Newswire release.
Study targets pancreatic cancer
The planned Phase 1/2 study will evaluate the combination in patients with MTAP-deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the trial, while Erasca will supply ERAS-0015.
Navlimetostat, also known as BMS-986504, is an investigational PRMT5 inhibitor. ERAS-0015 is Erasca's investigational oral pan-RAS molecular glue. The companies said they will retain development and commercial rights to their respective compounds, and described the agreement as mutually non-exclusive.
Scientific rationale and next steps
Erasca said nearly all MTAP-deleted pancreatic cancers carry co-occurring RAS mutations. The collaboration therefore seeks to study simultaneous RAS and PRMT5 inhibition, although the clinical benefit of the combination remains to be established.
Erasca is also evaluating ERAS-0015 in its AURORAS-1 Phase 1 trial for patients with RAS-mutant solid tumors. The press release cited early findings including partial responses in several patients, but further clinical work will be needed to assess the combination's safety and effectiveness.
Bristol Myers Squibb stock traded at 55.68 euros on Lang & Schwarz at 15:38 CET on Wednesday, November 18, 2026.
Bristol Myers Squibb at a glance
- Company: Bristol Myers Squibb
- ISIN: US1101221083
- Trading venue: Lang & Schwarz
- Quoted price: 55.68 euros at 15:38 CET on November 18, 2026
- New collaboration: Erasca clinical trial and supply agreement
US equities remain in focus alongside current market reports.
